Clinical trial REASSURE
REASSURE, Radium-223 alpha Emitter Agent in Safety Study in mCRPC popUlation for long-teRm Evaluation (Bayer 16913)
| Cancers | |
|---|---|
| Organ | prostate |
| Trial status | Trial closed |
| Trial type |
Prospective observational study
|
| Phase | Trial phase 4 |
| Academic trial | Non |
| Sponsor | Bayer |
| BECT Identifier | B403201524066 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02141438 |
| Inclusion criteria | - The treatment decision to Radium-223 needs to be made independent from andbefore patient enrollment in the study- Patients with histologically or cytologically confirmed castration resistantadenocarcinoma of the prostate with bone metastases |
| Last update |